AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01344681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever.
Study NCT02174367 — intervention group
Intervention type: DEVICE
Intervention: Transient elastography
Description: a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
Study NCT03015649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAVI SCOUT Surgical Guidance System
Description: SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
Study NCT02041975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutriose FB06
Description: Wheat dextrin soluble fibre
Study NCT02041975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04347213 — intervention group
Intervention type: BEHAVIORAL
Intervention: Regular lifestyle in different circumstances
Description: Participants' lifestyle will be followed over the years.
Study NCT01812759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone PCA
Description: Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
Study NCT00927784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor cells (RevascorTM)
Description: Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
Study NCT00927784 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cryoprotective media alone
Description: Participants will receive intramyocardial injections of cryoprotective media (placebo).
Study NCT03498690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrative
Description: Stakeholder groups: a-b
Study NCT03498690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Role specific
Description: Stakeholder groups: a or b
Study NCT01812759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: 1 placebo nasal spray administered in each nostril.
Study NCT03986359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
Study NCT03986359 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
Study NCT03835559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate closure
Description: After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
Study NCT03835559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical stripping
Description: All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
Study NCT03498690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive
Description: Stakeholder groups: a=> b
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be dosed per the pharmacy manual
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be dosed per the pharmacy manual
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel will be dosed per local practice and label
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be dosed per local practice and label
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be dosed per the pharmacy manual
Study NCT03138889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be dosed per current label indication
Study NCT04164446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo that will be used contains starch and glucose.
Study NCT04164446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil Palm Phenolics
Description: One capsule contains 250 mg OPP or 1 g OPP
Study NCT01934660 — intervention group
Intervention type: DRUG
Intervention: 13N-amonia
Study NCT04851392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
Description: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
Study NCT01186679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laminectomy
Description: surgical laminectomy with glial scar resection
Study NCT01186679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal
Description: direct into the CSF through lumbar puncture
Study NCT02259582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Study NCT02259582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study NCT02259582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study NCT02259582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT02259582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: demcizumab
Study NCT01015872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
Study NCT00949117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Given orally
Study NCT00584090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate (VESIcare)
Description: 5 - 10 mg po qd for 1 month
Study NCT00584090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent of 5-10 mg po qd for 1 month
Study NCT01053728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR161271
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study NCT01598558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-64 Rituximab
Description: Up to 14 mCi, iv
Study NCT04851392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis with THC without CBD
Description: Cannabis with THC without CBD - inhaled and vaporised cannabis flower
Study NCT04851392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cannabis
Description: Placebo cannabis, without THC and without CBD - inhaled and vaporised
Study NCT00713349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xenaderm Vehicle
Description: Ointment to be applied three times a day on cryo-surgery wound for 21 days.
Study NCT00713349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Ointment to be applied three times a day on cryo-surgery wound for 21 days.
Study NCT02706275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External warming
Description: External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
Study NCT04301479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone sodium succinate
Description: Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
Study NCT04301479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
Study NCT01741883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Side effect prevention training (SEPT)
Description: SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
Study NCT01741883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control group (ACG)
Description: Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
Study NCT01069874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vitamin D/Vigantol oil)
Description: Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
Study NCT01069874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Miglyol oil
Description: Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
Study NCT01189786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent system
Description: A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
Study NCT04077190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells
Description: 5cc adipose derived stem cells.
Study NCT04077190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cortisone injection
Description: cortisone injection
Study NCT01053728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study NCT03458260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone
Description: 6 cycles - dose = 80mg/m²
Study NCT03458260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 6 cycles - 1500 mg/m2
Study NCT03458260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 6 cycles - 150 mg/m2
Study NCT03458260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 6 cycles - 375 mg/m2
Study NCT03458260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplant
Description: after 2 or 6 cycles
Study NCT01374984 — intervention group
Intervention type: BIOLOGICAL
Intervention: VIGIV
Description: VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
Study NCT01969786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal ulcer prevention program
Description: The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
Study NCT01596309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa extract
Description: Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
Study NCT01596309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract
Description: Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
Study NCT03813615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill walking (Proof-of-Concept)
Description: Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
Study NCT03813615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill walking Dose-Finding / Escalation
Description: Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk \& 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity \& duration) or non-linear (i.e., exercise dose is continually altered \& progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented \& may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
Study NCT02974712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT02974712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT04060095 — intervention group
Intervention type: PROCEDURE
Intervention: standardized noxious stimulus under general anesthesia.
Description: 50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient.
Study NCT01363882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep study-guided adjustment of NIV
Description: Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
Study NCT01363882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard initiation of NIV
Description: NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
Study NCT02537587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control 1
Description: 67g of control bar
Study NCT02537587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control 2
Description: 86g of control bar
Study NCT02537587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15/0
Description: 66g of experimental bar 15/0
Study NCT02537587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15/0LS
Description: 84g of experimental bar 15/0LS
Study NCT02537587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15/5
Description: 75g of experimental bar 15/5
Study NCT02537587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10/5
Description: 72g of experimental bar 10/5
Study NCT02537587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10/10
Description: 80g of experimental bar 10/10
Study NCT05271032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: use of Trasnpulmonary termodiluetion technique
Description: All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
Study NCT02553980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow Your Virtual Trainer (FYVT) program
Description: Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed.
Study NCT02553980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Daily PA recommendation & healthy lifestyle suggestions
Description: A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
Study NCT03546595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupoints acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
Study NCT03546595 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupoints acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
Study NCT02342717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: single dose BI 425809 tablet
Study NCT02342717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: multiple doses of Itraconazole capsules